STRATEC Annual General Meeting resolves dividend payment amounting to EUR 0.70 per share

Birkenfeld, May 22, 2015

The Shareholders of STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) approved all of the agenda items put to the vote at today's Annual General Meeting in Pforzheim with the necessary majorities in each case. The shareholders present represented 72.85% of the company's share capital.

As proposed, STRATEC will distribute a dividend of EUR 0.70 per share to its shareholders for the 2014 financial year (previous year: EUR 0.60). The distribution total amounts to EUR 8.2 million and will be paid to shareholders via their depository banks on May 26, 2015. The dividend has thus been increased for the eleventh year in succession since the initiation of dividend payments in 2004.

Furthermore, Ebner Stolz GmbH & Co. KG, Stuttgart, was elected as auditor for the 2015 financial year. It was also decided to convert the company's shares from bearer to registered shares. This conversion is due to be implemented in the second half of 2015.

The Annual General Meeting also once again approved the creation of authorized and conditional capitals, an authorization to acquire and sell own shares, and various amendments to the Articles of Association.

Further information about our Annual General Meeting can be found on the company's website at www.stratec.com/agm, where details of voting results have also been published.

About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.
Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.

Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Investor Relations
Gewerbestr. 37,
75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir@stratec.com
www.stratec.com